Switzerland is slipping further down the European rankings when it comes to access to new innovative medicines: according to IQVIA’s EFPIA WAIT Indicator 2024, Switzerland has dropped another place, falling from sixth to seventh. It is particularly alarming that only around half as many new innovative medicines are reimbursed as standard via the specialty list as in Germany – and the trend is downward [1].
Autoren
- Birke Dikken
Publikation
- InFo ONKOLOGIE & HÄMATOLOGIE
Related Topics
You May Also Like
- Immunotherapy
Subcutaneously or intravenously?
- Cannabis - medical vs. non-medical use
Interim assessment: the boundaries are fluid
- Case Report
Cutaneous myiasis caused by botfly larvae
- Chronic insomnia, REM sleep instability and emotional dysregulation
Risk factors for anxiety and depression
- Immune sensors
Dysfunctional signaling pathways in cardiomyocytes and their role in heart disease
- Inoperable NSCLC
Efficacy of pembrolizumab in combination with concurrent chemoradiotherapy
- Dementia
Recognize incipient progression and identify countermeasures
- Subtype-specific risks and implications for neurological care